嗜铬细胞瘤-副神经节瘤
Pheochromocytoma-paraganglioma
定义
一种罕见的神经内分泌肿瘤，产生于肾上腺髓质的嗜铬细胞瘤（嗜铬细胞瘤）或交感神经节和副交感神经节（副神经节瘤）。这些肿瘤最常见的是良性的，可能会产生过多的儿茶酚胺，引起高血压，有时还会引起严重的急性心血管并发症。
近两年的全球研究 402L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-07Histological spectrum of resected adrenal tumors in the 11-20 HU grey zone on unenhanced CT: a retrospective cohort study
- 2026-07病例报告Expansion of Germline Variants in Primary Hyperparathyroidism: Fumarate Hydratase Deficiency as a Cause of Parathyroid Adenomas
- 2026-07A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma
- 2026-07Clinical Impact of Germline Multigene Sequencing in Pediatric Cohorts with a Wide Spectrum of Neoplasms
- 2026-07OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
- 2026-07Systemic management of adrenal malignancies: adrenocortical carcinoma and pheochromocytoma/paraganglioma
- 2026-07Clinical presentation and outcomes of sporadic neuroendocrine neoplasms in young adults
- 2026-06Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma: A Potential Diagnostic Pitfall
- 2026-06综述Adrenal tumor microenvironment: hormone-immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities
- 2026-06开放获取Recurrent PRES in a Patient With Cyclic Vomiting Syndrome
- 2026-06开放获取Retroperitoneal Extra-Adrenal Paraganglioma Presenting With Secondary Amenorrhea and Hypertension in an Adolescent: A Rare Case From Sub-Saharan Africa
- 2026-06Outcomes With Peptide Receptor Radionuclide Therapy in Patients With Pheochromocytoma/Paraganglioma: A Center of Excellence Experience
- 2026-06病例报告Synchronous Bilateral Carotid Body and Bilateral Vagal Paragangliomas: A Case Report and Literature Review
- 2026-06综述开放获取The cGAS-STING pathway in cancer immunotherapy: prognostic value and therapeutic potential
- 2026-06病例报告开放获取Synchronous Bilateral Carotid Body and Bilateral Vagal Paragangliomas: A Case Report and Literature Review
- 2026-06开放获取Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?
- 2026-06Pan-cancer atlas of ITGA6 unveils its multifaceted oncogenic roles and therapeutic potential in uveal melanoma
- 2026-06综述开放获取Genetics of familial acromegaly and pituitary gigantism
- 2026-06综述Effects of catecholamines on bone and mineral metabolism in patients with pheochromocytoma and paraganglioma
- 2026-05综述开放获取Updates on Minimally Invasive Treatment of Adrenal Tumors
境外已获批用于本病的药物 1L2
欧盟 0 项、美国 1 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Iobenguane Sulfate I 131美国1994-03-25官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 20L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 8
- 招募中NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)中国研究中心 4 个：Beijing、Chengdu、Guangzhou、Shanghai
- 招募中NCT0506922018F-MFBG PET/CT in the Evaluation of Neural Crest Tumor中国研究中心 1 个：Beijing
- 招募中NCT0681374218F-mFBG PET Imaging in the Evaluation of Pheochromocytoma中国研究中心 2 个：Hangzhou
- 招募中NCT07288931Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma中国研究中心 1 个：Beijing
- 仅邀请入组NCT07182175Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors中国研究中心 1 个：Beijing
- 招募中NCT06683846Ivonescimab in the Treatment of Multiple Advanced Tumors中国研究中心 1 个：Shanghai
- 招募中NCT07195500Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma中国研究中心 1 个：Nanjing
- 尚未开始招募NCT06429397Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma中国研究中心 1 个：Guangzhou
其他状态的试验（12 项）
- 已完成NCT07412158Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)中国研究中心 1 个：Beijing
- 已完成NCT05858177The Efficacy and Safety of Temozolomide in Patients With MPPGL中国研究中心 1 个：Beijing
- 已完成NCT06669481Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics中国研究中心 1 个：Beijing
- 已完成NCT04860700The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma中国研究中心 1 个：Beijing
- 状态未知NCT04890444China Adrenal Disease Registry中国研究中心 1 个：Shanghai
- 状态未知NCT05133349A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial中国研究中心 1 个：Nanjing
- 状态未知NCT05883085A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL中国研究中心 1 个：Beijing
- 状态未知NCT05451134Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma中国研究中心 1 个：Beijing
- 状态未知NCT05752773Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection中国研究中心 1 个：Beijing
- 状态未知NCT06015061Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients中国研究中心 1 个：Beijing
- 状态未知NCT05885386A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL中国研究中心 1 个：Beijing
- 状态未知NCT05885399The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment中国研究中心 1 个：Beijing
中国境外的在招试验 47L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国22意大利3加拿大2英国2西班牙1阿根廷1荷兰1巴西1丹麦1韩国1墨西哥1瑞士1澳大利亚1新西兰1另有 3 个国家/地区
CT.gov 报告命中 47 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07743138STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)美国
- 尚未开始招募NCT07714551Zanzalintinib in Unresectable and Progressive MPGGs美国
- 尚未开始招募NCT07621146A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies加拿大
- 尚未开始招募NCT07538791Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)意大利
- 尚未开始招募NCT07661420211At-MABG in Adults With Advanced Neuroendocrine Cancers美国
- 招募中NCT07680205An Experimental Study of Belzutifan Impact on Catecholamine Metabolism英国
- 尚未开始招募NCT07516275Prospective Cohort Study of Pheochromocytoma/Paraganglioma
- 招募中NCT07282587Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma美国
- 招募中NCT04119024Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors美国
- 尚未开始招募NCT07200245Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors
- 招募中NCT0650314618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection美国
- 招募中NCT06479811[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers美国
- 招募中NCT06427798Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy美国
- 招募中NCT07072143An International Study on Pediatric Patients With Rare Tumors.意大利
- 招募中NCT06607692Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).西班牙
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）